The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Cluster headache (CH) is a stereotyped primary headache characterized by strictly unilateral severe orbital or periorbital pain and categorized as either episodic or chronic (1,2). Its prevalence is 0.1% (3). Oxygen and sumatriptan are the treatments of choice for individual attacks, whereas verapamil, lithium, corticosteroids and other neuromodulators can suppress attacks during cluster periods (1). All standard medication treatments may be ineffective. Surgical treatment may be an option for medication non-responders, including deep brain (4) or occipital nerve stimulation (5). However, serious complications from brain surgery, including death, can occur (6). An Internet survey of 53 CH patients reported on claims that psilocybin is better at aborting acute attacks than either oxygen or sumatriptan and that LSD and psilocybin are both better at triggering and extending remission than standard drugs (7). However, due to hallucinogenicity and the absence of established medical indication, these drugs are criminalized and placed within the most restrictive Schedule I of the Controlled Substances Act, which sanctions only limited research use. Although the hallucinogenic properties of LSD and psilocybin are undesirable from both regulatory and patient safety perspectives, it was unclear to us at the outset whether a non-hallucinogenic analog could also provide meaningful relief to CH patients. To address the question of whether the CH relief associated with these two structural…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, 2-bromo-LSD (BOL-148, 5), despite its engagement with serotonin 5HT2A receptors, does not evoke hallucinations [12], except perhaps in rare cases [13].”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [12]
Citations
Cites
Goadsby, P. J. (2004) · Cephalalgia · doi:10.1111/j.1468-2982.2004.00711.x · Cited by 2,381
The International Classification of Headache Disorders
Olesen, J. (2008) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2008.01121.x · Cited by 2,321
The pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455
Self-citationEFNS guidelines on the treatment of cluster headache and other trigeminal‐autonomic cephalalgias
May, A., Leone, M., Áfra, J., Linde, M., Sándor, P. S., Evers, S., & Goadsby, P. J. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01566.x · Cited by 413
Cluster headache: pathogenesis, diagnosis, and management
May, A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67217-0 · Cited by 378
Hypothalamic stimulation in chronic cluster headache: a pilot study of efficacy and mode of action
Schoenen, J. (2005) · Brain · doi:10.1093/brain/awh411 · Cited by 373
Response of cluster headache to psilocybin and LSD
Sewell, R. A., Halpern, J. H., & Pope, H. G. (2006) · Neurology · doi:10.1212/01.wnl.0000219761.05466.43 · Cited by 259
Self-citationHypothalamic stimulation for intractable cluster headache: Long-term experience
Leone, M., Franzini, A., Broggi, G., & Bussone, G. (2006) · Neurology · doi:10.1212/01.wnl.0000223319.56699.8a · Cited by 212
Current concepts in migraine research
Hanington, E. (1978) · Neuroscience · doi:10.1016/0306-4522(78)90026-x · Cited by 151
Kohn, B., & Hofmann, A. (1981) · The Antioch Review · doi:10.2307/4638477 · Cited by 144
Cluster Headache in The Republic Of San Marino
D'Alessandro, R., Gamberini, G., Benassi, G., Morganti, G., Cortelli, P., & Lugaresi, E. (1986) · Cephalalgia · doi:10.1046/j.1468-2982.1986.0603159.x · Cited by 132
Placebo Response in Cluster Headache Trials: A Review
Remahl, A. I. M. N., Meyer, E. L., Cordonnier, C., & Goadsby, P. J. (2003) · Cephalalgia · doi:10.1046/j.1468-2982.2003.00531.x · Cited by 84
Neurostimulation approaches to primary headache disorders
Bartsch, T., Paemeleire, K., & Goadsby, P. J. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32832ae61e · Cited by 82
Acquired and Crossed Tolerance to Mescaline, LSD-25, and BOL-148
BALESTRIERI, A. (1959) · Archives of General Psychiatry · doi:10.1001/archpsyc.1959.03590030063008 · Cited by 75
Outpatient Intravenous Dihydroergotamine for Refractory Cluster Headache
Magnoux, E., & Zlotnik, G. (2004) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2004.04055.x · Cited by 64
History of Methysergide in Migraine
Koehler, P. J., & Tfelt-Hansen, P. (2008) · Cephalalgia · doi:10.1111/j.1468-2982.2008.01648.x · Cited by 57
Troxler, F., & Hofmann, A. A. (1957) · Helvetica Chimica Acta · doi:10.1002/hlca.19570400716 · Cited by 42
Troxler, F., & Hofmann, A. A. (1957) · Helvetica Chimica Acta · doi:10.1002/hlca.19570400619 · Cited by 37
PROPHYLACTIC TREATMENT OF MIGRAINE BY MEANS OF LYSERGIC ACID DERIVATIVES.
Sicuteri, F. (1963) · PubMed · Cited by 35
Cholinesterase, dlysergic acid diethylamide, and 2-bromolysergic acid diethylamide.
Bertino, J. R., Klee, G. D., & Weintraub, W. (1959) · PubMed · Cited by 21
Clark, L. D., & BLISS, E. L. (1957) · A M A Archives of Neurology & Psychiatry · doi:10.1001/archneurpsyc.1957.02330420113020 · Cited by 20
Yapp, N. (1991) · Penguin Books · Cited by 16
CHEMOTHERAPEUTIC TRIALS IN PSYCHOSIS: III. ADDENDUM
Turner, W. J., ALMUDEVAR, M., & Merlis, S. (1959) · American Journal of Psychiatry · doi:10.1176/ajp.116.3.261 · Cited by 14
Retroperitoneal fibrosis in two patients previously exposed to LSD.
Aptekar, R. G., & Mitchinson, M. J. (1970) · PubMed Central · Cited by 10
Frood, A. (2006) · Nature Medicine · doi:10.1038/nm0107-10 · Cited by 9
Research works printed but not linked: 3
- Bertino JR, 1959, J Clin Exp Psychopath, 20, 218
- Sicuteri F, 1963, Triangle, 6, 116
- Aptekar RG, 1970, Calif Med, 113, 77
Cited by
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Effects of Schedule I drug laws on neuroscience research and treatment innovation
Nutt, D. J., King, L. A., & Nichols, D. E. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3530 · Cited by 337
Potential Therapeutic Effects of Psilocybin
Johnson, M. W., & Griffiths, R. R. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0542-y · Cited by 296
Majić, T., Schmidt, T. T., & Gallinat, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568040 · Cited by 261
Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential
Wallach, J., Cao, A. B., Calkins, M. M., Heim, A. J., Lanham, J. K., Bonniwell, E. M., Hennessey, J. J., Bock, H. A., Anderson, E. I., Sherwood, A. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44016-1 · Cited by 170
Metadata
- Authors
- Karst, M., Halpern, J. H., Bernateck, M., & Passie, T.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Harvard University (US)
- Corresponding author
- Karst, Matthias
- Venue
- Cephalalgia
- Publisher
- SAGE Publications
- Published
- 2010-03-26
- Volume
- 30
- Issue
- 9
- Pages
- 1140-1144
- ISSN
- 0333-1024 (ISSN-L)
- 1468-2982
- OpenAlex
- W2151828427
- Cited by
- 106
- References
- 25
- Citations by year
- 2026: 3 · 2025: 15 · 2024: 14 · 2023: 19 · 2022: 9 · 2021: 5 · 2020: 4 · 2019: 2 · 2018: 4 · 2017: 3 · 2016: 4 · 2015: 3 · 2014: 3 · 2013: 7 · 2012: 6
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Cephalalgia (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Migraine and Headache Studies
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Keywords
- cluster headache, prophylaxis, serotonin receptor agonists, 5-HT1A receptor, 5-HT2A receptor, 5-HT3 receptor, 5-HT4 receptor, 5-HT6 receptor
- MeSH terms
- Adult, Cluster Headache, Female, Hallucinogens, Humans, Lysergic Acid Diethylamide, Male, Middle Aged, Severity of Illness Index, Sympathetic Nervous System, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.